

**FORM 51-102F3
MATERIAL CHANGE REPORT**

Item 1. Name and Address of Company

Izotropic Corporation (the “**Company**”)
15718 39A Avenue
Surrey, BC V3Z 0L1

Item 2. Date of Material Change

August 13, 2018

Item 3. News Release

The News Release dated August 13, 2018 was disseminated by Stockwatch and Market News on August 13, 2018.

Item 4. Summary of Material Change

The Company announced a non-brokered private placement financing (the “**Offering**”) of up to 500,000 units of the Company (each, a “**Unit**”) at a price of \$0.20 per Unit for gross proceeds of up to \$100,000. Each Unit will consist of one common share and one share purchase warrant (each, a “**Warrant**”), and each Warrant will entitle the holder to purchase one additional share at a price of \$0.40 per share for a period of one year from closing of the Offering.

Completion of the Offering is subject to a number of conditions, including, without limitation, receipt of all necessary regulatory approvals. Finders’ fees may be paid in connection with the Offering.

All securities issued in connection with the Offering will be subject to a statutory hold period of four months and one day from the date of issuance in accordance with applicable securities legislation.

None of the securities issued in the Offering will be registered under the *United States Securities Act of 1933*, as amended (the “**1933 Act**”), and none of them may be offered or sold in the United States absent registration or an applicable exemption from the registration requirements of the 1933 Act. This news release shall not constitute an offer to sell or a solicitation of an offer to buy nor shall there be any sale of the securities in any state where such offer, solicitation, or sale would be unlawful.

Item 5. Full Description of Material Change

5.1 Full Description of Material Change

See attached August 13, 2018 News Release.

5.2 Disclosure for Restructuring Transactions

Not Applicable.

Item 6. Reliance on subsection 7.1(2) or (3) of National Instrument 51-102

Not Applicable.

Item 7. Omitted Information

None.

Item 8. Executive Officer

Please contact Robert Thast, Chief Executive Officer of the Company, at 604-542-9458.

Item 9. Date of Report

August 13, 2018

THIS NEWS RELEASE IS NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES FOR DISSEMINATION IN THE UNITED STATES

IZOTROPIC CORPORATION

IZOTROPIC CORPORATION ANNOUNCES NON-BROKERED PRIVATE PLACEMENT

VANCOUVER, BC – August 13, 2018 – **Izotropic Corporation** (“**Izotropic**” or the “**Company**”) (CSE: IZO) is pleased to announce a non-brokered private placement financing (the “**Offering**”) of up to 500,000 units of the Company (each, a “**Unit**”) at a price of \$0.20 per Unit for gross proceeds of up to \$100,000. Each Unit will consist of one common share and one share purchase warrant (each, a “**Warrant**”), and each Warrant will entitle the holder to purchase one additional share at a price of \$0.40 per share for a period of one year from closing of the Offering.

Completion of the Offering is subject to a number of conditions, including, without limitation, receipt of all necessary regulatory approvals. Finders’ fees may be paid in connection with the Offering.

All securities issued in connection with the Offering will be subject to a statutory hold period of four months and one day from the date of issuance in accordance with applicable securities legislation.

None of the securities issued in the Offering will be registered under the *United States Securities Act of 1933*, as amended (the “**1933 Act**”), and none of them may be offered or sold in the United States absent registration or an applicable exemption from the registration requirements of the 1933 Act. This news release shall not constitute an offer to sell or a solicitation of an offer to buy nor shall there be any sale of the securities in any state where such offer, solicitation, or sale would be unlawful.

About Izotropic

The Company is engaged in the development and commercialization of next generation 3-D breast CT imaging technology for early diagnosis of breast cancer, that improves patient comfort, provides a true 360-degree view acquisition and delivers high diagnostic accuracy.

ON BEHALF OF THE BOARD

“Robert Thast”

Robert Thast

Chief Executive Officer, Director
and Promoter

For further information, please contact:

Robert Thast
Telephone: 604.542.9458

Email: bthast@telus.net

Forward-Looking Statements

This news release contains forward-looking statements. All statements, other than statements of historical fact that address activities, events or developments that the Company believes, expects or anticipates will or may occur in the future are forward-looking statements. Forward-looking statements in this news release include statements regarding the proceeds to be raised pursuant to the Offering and resale restrictions relating to the securities to be issued. The forward-looking statements reflect management's current expectations based on information currently available and are subject to a number of risks and uncertainties that may cause outcomes to differ materially from those discussed in the forward-looking statements including: (i) adverse market conditions; (ii) the inability of the Company to complete the Offering at all or on the terms announced; or (iii) the Company not receiving all necessary regulatory approvals. Although the Company believes that the assumptions inherent in the forward-looking statements are reasonable, forward-looking statements are not guarantees of future performance and, accordingly, undue reliance should not be put on such statements due to their inherent uncertainty. Factors that could cause actual results or events to differ materially from current expectations include general market conditions and other factors beyond the control of the Company. The Company expressly disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise, except as required by applicable law.